Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context

Inclusion Criteria: * Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied), * Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept, * Patient using effective contraception if he is of childbearing age * Patient informed and not having made his opposition to the research, * Patient under social security scheme. Exclusion Criteria: * Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye, * Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept, * Aphakia in the studied eye, * Fibrosis or retrofoveolar retinal atrophy of the eye studied, * Tearing of the pigment epithelium reaching my macula of the studied eye, * Choroidal neovascularization unrelated to AMD, * Diabetic retinopathy and / or diabetic maculopathy proven, * Glycated hemoglobin greater than 12%, * Known hypersensitivity to pharmaceutical agents used, * Pregnant or lactating women, * Severe active intraocular inflammation, or history autoimmune or idiopathic uveitis, * Active or suspected ocular or periocular infection, * Intraocular pressure\> 25mmHg despite two hypotonizing treatments in eye drops, * Patient under tutorship or curatorship or private public law.